CN109010593A - 一种安神补虚药物组合物及其制备方法及应用 - Google Patents
一种安神补虚药物组合物及其制备方法及应用 Download PDFInfo
- Publication number
- CN109010593A CN109010593A CN201811079903.8A CN201811079903A CN109010593A CN 109010593 A CN109010593 A CN 109010593A CN 201811079903 A CN201811079903 A CN 201811079903A CN 109010593 A CN109010593 A CN 109010593A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- radix
- ginseng
- fruit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 38
- 230000002936 tranquilizing effect Effects 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims description 20
- 210000000582 semen Anatomy 0.000 claims abstract description 48
- 241000005787 Cistanche Species 0.000 claims abstract description 24
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 24
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 24
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 22
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 22
- 235000008434 ginseng Nutrition 0.000 claims abstract description 22
- 244000197580 Poria cocos Species 0.000 claims abstract description 15
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 15
- 241001078983 Tetradium ruticarpum Species 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 claims abstract description 15
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 14
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims abstract description 7
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims abstract description 7
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 57
- 235000019441 ethanol Nutrition 0.000 claims description 30
- 238000001914 filtration Methods 0.000 claims description 27
- 241000208340 Araliaceae Species 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 16
- 239000012141 concentrate Substances 0.000 claims description 14
- 230000001376 precipitating effect Effects 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 229940107131 ginseng root Drugs 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000013372 meat Nutrition 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 3
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 9
- 201000005202 lung cancer Diseases 0.000 description 9
- 208000020816 lung neoplasm Diseases 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 6
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 229960002584 gefitinib Drugs 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000007958 sleep Effects 0.000 description 3
- 230000036578 sleeping time Effects 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003500 flue dust Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000009936 smoking Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种安神补虚药物组合物,原料药组成及重量份为:酸枣仁100‑250份,人参50‑100份,吴茱萸100‑200份,麦冬100‑200份,白术100‑200份,五味子70‑160份,茯苓60‑150份,柴胡50‑150份,黄芩50‑150份,肉苁蓉50‑100份,菟丝子50‑100份,女贞子50‑100份,熟地50‑100份。经过临床试验,本发明的药物可明显改善酪氨酸激酶抑制剂导致失眠,效果显著。
Description
技术领域
本发明涉及一种安神补虚药物组合物,特别涉及一种安神补虚药物组合物及其制备方法及应用。
背景技术
肺癌是发病率和死亡率增长最快,对人群健康和生命威胁最大的恶性肿瘤之一。近50年来许多国家都报道肺癌的发病率和死亡率均明显增高,男性肺癌发病率和死亡率均占所有恶性肿瘤的第一位,女性发病率占第二位,死亡率占第二位。肺癌的病因至今尚不完全明确,大量资料表明,长期大量吸烟与肺癌的发生有非常密切的关系。已有的研究证明:长期大量吸烟者患肺癌的概率是不吸烟者的10~20倍,开始吸烟的年龄越小,患肺癌的几率越高。此外,吸烟不仅直接影响本人的身体健康,还对周围人群的健康产生不良影响,导致被动吸烟者肺癌患病率明显增加。城市居民肺癌的发病率比农村高,这可能与城市大气污染和烟尘中含有致癌物质有关。
吉非替尼由美国哈佛大学医学院最先研究,是一种选择性表皮生长因子受体(EGFR)酪氨酸激酶抑制剂,该酶通常表达于上皮来源的实体瘤。吉非替尼广泛抑制异种移植于裸鼠的人肿瘤细胞的生长,抑制其血管生成。在体外,可增加人肿瘤细胞衍生系的凋亡,并抑制血管生成因子的侵入和分泌。在动物试验或体外研究中已证实,吉非替尼可提高化疗、放疗及激素治疗的抗肿瘤活性。吉非替尼竞争EGFR-TK催化区域上Mg-ATP结合位点,阻断其信号传递;抑制有丝分裂原活化蛋白激酶的活化,促进细胞凋亡;抑制肿瘤血管生成。Iressa已于2002年7月5日经日本厚生省批准用于治疗晚期NSCLC,2003年5月5日被FDA批准作为NSCLC的三线治疗药物,其推荐剂量为250mg,PO,qd。
肺癌患者临床使用该药,会带来失眠等不良作用,影响患者的生存质量,而临床缺乏相应的药物。
发明内容
本发明目的在于公开一种安神补虚药物组合物,及其制备方法及用途。
本发明目的是通过如下技术方案实现的:
一种安神补虚药物组合物,原料药组成及重量份为:酸枣仁100-250份,人参50-100份,吴茱萸100-200份,麦冬100-200份,白术100-200份,五味子70-160份,茯苓60-150份,柴胡50-150份,黄芩50-150份,肉苁蓉50-100份,菟丝子50-100份,女贞子50-100份,熟地50-100份。
进一步,所述的药物组合物,该药物组合物的原料药组成及重量份为:酸枣仁150-250份,人参60-90份,吴茱萸120-180份,麦冬120-180份,白术120-180份,五味子80-150份,茯苓70-120份,柴胡60-140份,黄芩60-120份,肉苁蓉60-90份,菟丝子60-90份,女贞子60-90份,熟地60-90份。
优选的,所述的药物组合物,该药物组合物的原料药组成及重量份为:酸枣仁250份,人参90份,吴茱萸180份,麦冬160份,白术160份,五味子120份,茯苓100份,柴胡100份,黄芩90份,肉苁蓉80份,菟丝子90份,女贞子80份,熟地60份。
优选的,所述的药物组合物,该药物组合物的原料药组成及重量份为:酸枣仁200份,人参60份,吴茱萸120份,麦冬120份,白术120份,五味子80份,茯苓80份,柴胡80份,黄芩70份,肉苁蓉70份,菟丝子70份,女贞子70份,熟地70份。
优选的,所述的药物组合物,该药物组合物的原料药组成及重量份为:酸枣仁150份,人参70份,吴茱萸120份,麦冬120份,白术130份,五味子140份,茯苓100份,柴胡80份,黄芩60份,肉苁蓉90份,菟丝子60份,女贞子60份,熟地60份。
所述的药物组合物,其剂型为颗粒剂、胶囊剂、片剂等口服制剂。
所述的药物组合物的制备方法,其特征在于步骤为:
(1)将酸枣仁,肉苁蓉,菟丝子,女贞子原料药材混合,加6-10倍量的20-50%乙醇,调整PH值为7.5-8.5,浸泡2-6小时,渗漉提取,合并提取液、过滤,减压回收乙醇,浓缩至浸膏;
(2)将人参打粉,其余药材和步骤(1)的药渣加水煎煮0.5-1小时,煎煮2次,过滤,加入50%乙醇,搅拌,放置2-4℃环境,静置24-48小时,过滤去除沉淀,上清液回收乙醇后,浓缩后,加水溶解,过滤去除沉淀,浓缩得浓缩液;
(3)将步骤(1)的浸膏和步骤(2)的浓缩液,人参粉末搅拌均匀,制成颗粒。
优选的,步骤(1)中,将酸枣仁,肉苁蓉,菟丝子,女贞子原料药材混合,加6-8倍量的40%乙醇,调整PH值为78.0-8.5,浸泡2小时。
所述的药物组合物的制备方法,步骤为:
(1)将人参,酸枣仁,肉苁蓉,菟丝子,女贞子原料药材混合,加6-10倍量的20-50%乙醇,调整PH值为7.5-8.5,浸泡2-6小时,渗漉提取,合并提取液、过滤,减压回收乙醇,浓缩至浸膏;
(2)其余药材和步骤(1)的药渣加水煎煮0.5-1小时,煎煮2次,过滤,加入50%乙醇,搅拌,放置2-4℃环境,静置24-48小时,过滤去除沉淀,上清液回收乙醇后,浓缩后,加水溶解,过滤去除沉淀,浓缩得浓缩液;
(3)将步骤(1)的浸膏和步骤(2)的浓缩液,喷雾干燥,制成颗粒,压片或制成胶囊剂。
所述的药物组合物在制备中治疗酪氨酸激酶抑制剂导致失眠的药物中的应用。
本发明是发明人通过多年临床实践发现的方剂,君药酸枣仁养肝宁神,臣药人参大补元气,吴茱萸补阳通经络,麦冬和五味子滋肺阴,白术茯苓健脾,共为臣药,柴胡疏肝经,黄芩清虚热,肉苁蓉补肾阳,工位佐药,菟丝子女贞子补肾,熟地补肾阴共为使药。诸药共用,可安神补虚,疏肝清热。
本发明的药物具备安神补虚的效果。本发明的制备方法科学合理,克服了中药所含成分过多,复杂而带来制备困难的问题,有效成分保留多,效果显著。
经过临床试验,本发明的药物可明显改善酪氨酸激酶抑制剂导致失眠,效果显著。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。
实施例1一种安神补虚药物组合物
酸枣仁250份,人参90份,吴茱萸180份,麦冬160份,白术160份,五味子120份,茯苓100份,柴胡100份,黄芩90份,肉苁蓉80份,菟丝子90份,女贞子80份,熟地60份。。
制备方法为:
所述的药物组合物的制备方法,其特征在于步骤为:
(1)将酸枣仁,肉苁蓉,菟丝子,女贞子原料药材混合,加6-10倍量的20-50%乙醇,调整PH值为7.5-8.5,浸泡2-6小时,渗漉提取,合并提取液、过滤,减压回收乙醇,浓缩至浸膏;
(2)将人参打粉,其余药材和步骤(1)的药渣加水煎煮0.5-1小时,煎煮2次,过滤,加入50%乙醇,搅拌,放置2-4℃环境,静置24-48小时,过滤去除沉淀,上清液回收乙醇后,浓缩后,加水溶解,过滤去除沉淀,浓缩得浓缩液;
(3)将步骤(1)的浸膏和步骤(2)的浓缩液,人参粉末搅拌均匀,制成颗粒。
实施例2:一种安神补虚药物组合物
酸枣仁200份,人参60份,吴茱萸120份,麦冬120份,白术120份,五味子80份,茯苓80份,柴胡80份,黄芩70份,肉苁蓉70份,菟丝子70份,女贞子70份,熟地70份。
制备方法为:
所述的药物组合物的制备方法,其特征在于步骤为:
(1)将酸枣仁,肉苁蓉,菟丝子,女贞子原料药材混合,加6-8倍量的40%乙醇,调整PH值为78.0-8.5,浸泡2小时,渗漉提取,合并提取液、过滤,减压回收乙醇,浓缩至浸膏;
(2)将人参打粉,其余药材和步骤(1)的药渣加水煎煮0.5-1小时,煎煮2次,过滤,加入50%乙醇,搅拌,放置2-4℃环境,静置24-48小时,过滤去除沉淀,上清液回收乙醇后,浓缩后,加水溶解,过滤去除沉淀,浓缩得浓缩液;
(3)将步骤(1)的浸膏和步骤(2)的浓缩液,人参粉末搅拌均匀,制成颗粒。
实施例3:一种安神补虚药物组合物
酸枣仁150份,人参70份,吴茱萸120份,麦冬120份,白术130份,五味子140份,茯苓100份,柴胡80份,黄芩60份,肉苁蓉90份,菟丝子60份,女贞子60份,熟地60份。
制备方法为:
(1)将人参,酸枣仁,肉苁蓉,菟丝子,女贞子原料药材混合,加6-10倍量的20-50%乙醇,调整PH值为7.5-8.5,浸泡2-6小时,渗漉提取,合并提取液、过滤,减压回收乙醇,浓缩至浸膏;
(2)其余药材和步骤(1)的药渣加水煎煮0.5-1小时,煎煮2次,过滤,加入50%乙醇,搅拌,放置2-4℃环境,静置24-48小时,过滤去除沉淀,上清液回收乙醇后,浓缩后,加水溶解,过滤去除沉淀,浓缩得浓缩液;
(3)将步骤(1)的浸膏和步骤(2)的浓缩液,喷雾干燥,制成颗粒,压片或制成胶囊剂。
实施例4:临床实验试验
安神补虚颗粒对酪氨酸激酶抑制剂导致失眠的作用
1、临床资料
50例肺癌肿瘤患者为2016年3月至2017年3月我院患者,随机分为治疗组32和对照组18。
2、对照组给予酪氨酸激酶抑制剂吉非替尼进行常规治疗。
2.2治疗组:在对照组治疗基础上,给予安神补虚颗粒,每次5g,每日口服2次。
3、疗效标准
根据《临床睡眠疾病》中有关睡眠疾病的标准拟定治疗失眠的标准。
痊愈:半小时内入睡,睡眠时间在7h以上,睡眠深沉,醒后精神充沛。
显效:容易入睡,睡眠时间在6h以上,睡眠深度增加。
有效:入睡略困难,睡眠时间在5h以上,睡眠欠深度。
无效:治疗后失眠无明显改善或反加重者。
4、统计学方法
所得数据采用SPSS17.0软件进行处理,对两组患者疗效采用卡方检验。以P<0.05表示差异具有统计学意义。
3.3治疗结果
表1疗效实验结果
与对照组比较:*P<0.01
由表1可见,治疗组总有效率为87.5%,对照组为11.1%,两组比较差异具有统计学意义(P<0.01),提示治疗组总有效率优于对照组。
Claims (10)
1.一种安神补虚药物组合物,其特征在于:原料药组成及重量份为:酸枣仁100-250份,人参50-100份,吴茱萸100-200份,麦冬100-200份,白术100-200份,五味子70-160份,茯苓60-150份,柴胡50-150份,黄芩50-150份,肉苁蓉50-100份,菟丝子50-100份,女贞子50-100份,熟地50-100份。
2.如权利要求1所述的药物组合物,其特征在于该药物组合物的原料药组成及重量份为:酸枣仁150-250份,人参60-90份,吴茱萸120-180份,麦冬120-180份,白术120-180份,五味子80-150份,茯苓70-120份,柴胡60-140份,黄芩60-120份,肉苁蓉60-90份,菟丝子60-90份,女贞子60-90份,熟地60-90份。
3.如权利要求2所述的药物组合物,其特征在于该药物组合物的原料药组成及重量份为:酸枣仁250份,人参90份,吴茱萸180份,麦冬160份,白术160份,五味子120份,茯苓100份,柴胡100份,黄芩90份,肉苁蓉80份,菟丝子90份,女贞子80份,熟地60份。
4.如权利要求2所述的药物组合物,其特征在于该药物组合物的原料药组成及重量份为:酸枣仁200份,人参60份,吴茱萸120份,麦冬120份,白术120份,五味子80份,茯苓80份,柴胡80份,黄芩70份,肉苁蓉70份,菟丝子70份,女贞子70份,熟地70份。
5.如权利要求2所述的药物组合物,其特征在于该药物组合物的原料药组成及重量份为:酸枣仁150份,人参70份,吴茱萸120份,麦冬120份,白术130份,五味子140份,茯苓100份,柴胡80份,黄芩60份,肉苁蓉90份,菟丝子60份,女贞子60份,熟地60份。
6.如权利要求1至5任一所述的药物组合物,其特征在于,其剂型为颗粒剂、胶囊剂、片剂等口服制剂。
7.如权利要求1至5任一所述的药物组合物的制备方法,其特征在于步骤为:
(1)将酸枣仁,肉苁蓉,菟丝子,女贞子原料药材混合,加6-10倍量的20-50%乙醇,调整PH值为7.5-8.5,浸泡2-6小时,渗漉提取,合并提取液、过滤,减压回收乙醇,浓缩至浸膏;
(2)将人参打粉,其余药材和步骤(1)的药渣加水煎煮0.5-1小时,煎煮2次,过滤,加入50%乙醇,搅拌,放置2-4℃环境,静置24-48小时,过滤去除沉淀,上清液回收乙醇后,浓缩后,加水溶解,过滤去除沉淀,浓缩得浓缩液;
(3)将步骤(1)的浸膏和步骤(2)的浓缩液,人参粉末搅拌均匀,制成颗粒。
8.如权利要求7所述的药物组合物的制备方法,其特征在于:步骤(1)中,将酸枣仁,肉苁蓉,菟丝子,女贞子原料药材混合,加6-8倍量的40%乙醇,调整PH值为78.0-8.5,浸泡2小时。
9.如权利要求1至5任一所述的药物组合物的制备方法,其特征在于步骤为:
(1)将人参,酸枣仁,肉苁蓉,菟丝子,女贞子原料药材混合,加6-10倍量的20-50%乙醇,调整PH值为7.5-8.5,浸泡2-6小时,渗漉提取,合并提取液、过滤,减压回收乙醇,浓缩至浸膏;
(2)其余药材和步骤(1)的药渣加水煎煮0.5-1小时,煎煮2次,过滤,加入50%乙醇,搅拌,放置2-4℃环境,静置24-48小时,过滤去除沉淀,上清液回收乙醇后,浓缩后,加水溶解,过滤去除沉淀,浓缩得浓缩液;
(3)将步骤(1)的浸膏和步骤(2)的浓缩液,喷雾干燥,制成颗粒,压片或制成胶囊剂。
10.如权利要求1至5任一所述的药物组合物在制备中治疗酪氨酸激酶抑制剂导致失眠的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811079903.8A CN109010593B (zh) | 2018-09-17 | 2018-09-17 | 一种安神补虚药物组合物及其制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811079903.8A CN109010593B (zh) | 2018-09-17 | 2018-09-17 | 一种安神补虚药物组合物及其制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109010593A true CN109010593A (zh) | 2018-12-18 |
CN109010593B CN109010593B (zh) | 2021-04-20 |
Family
ID=64621933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811079903.8A Expired - Fee Related CN109010593B (zh) | 2018-09-17 | 2018-09-17 | 一种安神补虚药物组合物及其制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109010593B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101327297A (zh) * | 2008-07-27 | 2008-12-24 | 张继香 | 一种治疗失眠的中药组合物 |
CN101653553A (zh) * | 2009-08-10 | 2010-02-24 | 黄山 | 一种益心安神颗粒 |
-
2018
- 2018-09-17 CN CN201811079903.8A patent/CN109010593B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101327297A (zh) * | 2008-07-27 | 2008-12-24 | 张继香 | 一种治疗失眠的中药组合物 |
CN101653553A (zh) * | 2009-08-10 | 2010-02-24 | 黄山 | 一种益心安神颗粒 |
Non-Patent Citations (3)
Title |
---|
史俊芳等: "浅谈肝阳虚证", 《中国民间疗法》 * |
罗从容: "滋阴补肾法治疗老年性失眠86例疗效观察", 《贵阳中医学院学报》 * |
高俊杰等: "小柴胡汤治疗顽固性失眠2则", 《湖南中医杂志》 * |
Also Published As
Publication number | Publication date |
---|---|
CN109010593B (zh) | 2021-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102178100B (zh) | 一种低色氨酸杂交鸡饲料及其制备方法 | |
CN103251873B (zh) | 一种消食化积的中兽药 | |
CN101972338B (zh) | 一种治疗小儿上呼吸道感染的中药制剂及其制备方法 | |
CN103893722B (zh) | 一种治疗日光性皮炎的中药组合物及其制备方法 | |
CN104381691A (zh) | 用于预防仔猪营养不良性贫血的功能性饲料及其制备方法 | |
CN105231051A (zh) | 用于提高猪肉肉质风味的育肥猪用饲料及其制备方法 | |
CN101732564B (zh) | 一种用于抗癌的中药组合物、其制备方法和应用 | |
CN103169798A (zh) | 治疗梅尼埃病的中药组合物及其制备方法 | |
CN105596994A (zh) | 用于治疗肺癌细胞增殖的药物 | |
CN105746937A (zh) | 用于蛋鹅产蛋期的饲料及其制备方法 | |
CN105230973A (zh) | 一种育肥猪饲料及其制备方法 | |
CN109010593A (zh) | 一种安神补虚药物组合物及其制备方法及应用 | |
CN104688882A (zh) | 一种治疗小儿发热的中药组合物 | |
CN104491318A (zh) | 一种治疗哮喘的中药制剂及其制备方法 | |
CN110624060A (zh) | 一种治疗幼儿腹泻的中药制剂及其制备方法 | |
CN104491717B (zh) | 一种治疗乳腺增生的药物 | |
CN104223066A (zh) | 一种改善睡眠的中药组合物 | |
CN111388563B (zh) | 一种用于预防新生儿母乳性黄疸的组合物及其制备方法和应用 | |
CN104162090B (zh) | 一种药物组合物及其制备方法 | |
CN105795155A (zh) | 用于蛋鹅产蛋期的饲料预混料及其制备方法 | |
CN101020041A (zh) | 一种降血脂的保健品 | |
TWI302442B (en) | Process methods and compositions to treat dysmenorrhea and premenstrual syndrome | |
CN106110218A (zh) | 一种抗癌痛止痛贴及其制备方法 | |
CN104474440A (zh) | 用于治疗仔猪营养不良性贫血的药物组合物及其制备方法 | |
CN116474060A (zh) | 一种平衡阴阳改善睡眠的中药组合物、产品及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210420 |
|
CF01 | Termination of patent right due to non-payment of annual fee |